Trends in Factors Affecting Pregnancy Outcomes Among Women With Type 1 or Type 2 Diabetes of Childbearing Age (2004-2017).


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2020
Historique:
received: 19 08 2020
accepted: 30 11 2020
entrez: 11 3 2021
pubmed: 12 3 2021
medline: 4 6 2021
Statut: epublish

Résumé

To describe trends in modifiable and non-modifiable unfavorable factors affecting pregnancy outcomes, over time (years 2004-2017), in women with diabetes of childbearing age from an English primary care perspective. We identified women with diabetes aged 16-45 years from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network, an English primary care sentinel database. Repeated annual cross-sectional analyses (2004-2017) assessed the prevalence of unfavorable factors for pregnancy, such as obesity, poor glycaemic control, microalbuminuria, hypertension, use of medications for treating diabetes, and associated comorbidities not recommended for pregnancy. We identified 3,218 women (61.5% with Type 2 diabetes) in 2004 and 6,657 (65.0% with Type 2 diabetes) in 2017. The proportion of women with ideal glycaemic control for conception (HbA1c<6.5%) increased over time, in patients with Type 1 diabetes from 9.0% (7.1%-11.0%) to 19.1% (17.2%-21.1%), and in those with Type 2 diabetes from 27.2% (24.6%-29.9%) to 35.4% (33.6%-37.1%). The proportion of women with Type 2 diabetes prescribed medications different from insulin and metformin rose from 22.3% (20.5%-24.2%) to 27.3% (26.0%-28.6%).In 2017, 14.0% (12.6%-15.4%) of women with Type 1 and 30.7% (29.3%-32.0%) with Type 2 diabetes were prescribed angiotensin-modulating antihypertensives or statins. We captured at least one unfavorable factor for pregnancy in 50.9% (48.8%-52.9%) of women with Type 1 diabetes and 70.7% (69.3%-72.0%) of women with Type 2 diabetes. Only one third of women with Type 1 diabetes (32.2%, 30.3%-34.0%) and a quarter of those with Type 2 diabetes (23.1%, 21.9%-24.4%) were prescribed hormonal contraception. Contraception was prescribed more frequently to women with unfavorable factors for pregnancy compared to those without, however, the difference was significant only for women with Type 1 diabetes. Despite significant improvements in general diabetes care, the majority of women with Type 1 or Type 2 diabetes have unfavorable, although mostly modifiable, factors for the start of pregnancy. Good diabetes care for women of childbearing age should include taking into consideration a possible pregnancy.

Identifiants

pubmed: 33692751
doi: 10.3389/fendo.2020.596633
pmc: PMC7937966
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

596633

Informations de copyright

Copyright © 2021 Gaudio, Dozio, Feher, Scavini, Caretto, Joy, Van Vlymer, Hinton and de Lusignan.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Endocrinol Metab. 2016 Apr;101(4):1807-15
pubmed: 26918293
Diabetes Care. 2018 Jan;41(Suppl 1):S137-S143
pubmed: 29222384
BMJ Open. 2018 Aug 20;8(8):e020282
pubmed: 30127048
BMJ Open. 2016 Nov 24;6(11):e012801
pubmed: 27884846
Inform Prim Care. 2005;13(1):65-70
pubmed: 15949178
Diabet Med. 2014 Mar;31(3):357-65
pubmed: 24111989
BMJ Open. 2016 Apr 20;6(4):e011092
pubmed: 27098827
Diabet Med. 2013 Apr;30(4):457-63
pubmed: 23110381
Contraception. 2013 Feb;87(2):149-53
pubmed: 22878145
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
Digit Health. 2017 Aug 30;3:2055207617726418
pubmed: 29942610
BMJ. 2018 Jul 5;362:k2638
pubmed: 29976596
J Pak Med Assoc. 2016 Sep;66(9 Suppl 1):S74-7
pubmed: 27582159
Stud Health Technol Inform. 2018;255:65-69
pubmed: 30306908
Patient Relat Outcome Meas. 2017 Apr 06;8:43-56
pubmed: 28435343
Diabetologia. 2018 Jul;61(7):1528-1537
pubmed: 29744539
Diabet Med. 2006 May;23(5):481-4
pubmed: 16681556
Diabetes Ther. 2017 Apr;8(2):365-376
pubmed: 28324484
Diabetologia. 2017 Sep;60(9):1668-1677
pubmed: 28597075
Acta Diabetol. 2018 Feb;55(2):193-199
pubmed: 29209815
Stud Health Technol Inform. 2018;247:161-165
pubmed: 29677943
J Epidemiol Community Health. 2004 May;58(5):426-33
pubmed: 15082745
J Biomed Inform. 2014 Dec;52:364-72
pubmed: 25089026
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
BMC Public Health. 2012 Sep 17;12:792
pubmed: 22978747
Lancet. 2018 May 5;391(10132):1830-1841
pubmed: 29673873
Diabetes Care. 2010 Dec;33(12):2514-20
pubmed: 21115765

Auteurs

Mariangela Gaudio (M)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
International Medical Doctor Program, Vita-Salute San Raffaele University, Milan, Italy.

Nicoletta Dozio (N)

International Medical Doctor Program, Vita-Salute San Raffaele University, Milan, Italy.
Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Michael Feher (M)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
Nuffield Department of Primary Care Health Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Marina Scavini (M)

International Medical Doctor Program, Vita-Salute San Raffaele University, Milan, Italy.
Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Amelia Caretto (A)

International Medical Doctor Program, Vita-Salute San Raffaele University, Milan, Italy.
Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Mark Joy (M)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
Nuffield Department of Primary Care Health Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Jeremy Van Vlymer (J)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
Nuffield Department of Primary Care Health Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

William Hinton (W)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
Nuffield Department of Primary Care Health Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

Simon de Lusignan (S)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, United Kingdom.
Nuffield Department of Primary Care Health Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH